Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
27.11
+0.40 (1.50%)
Mar 4, 2026, 11:35 AM EST - Market open

Immunovant Income Statement

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
Selling, General & Admin
79.1577.2457.2848.0254.2339.51
Research & Development
408.02360.92225.43170.26101.8168.6
Total Operating Expenses
487.17438.15282.71218.28156.03108.12
Operating Income
-487.17-438.15-282.71-218.28-156.03-108.12
Interest Income
24.1624.7324.957.58--
Other Non-Operating Income (Expense)
2.450.47-1.01-0.25-0.78-0.33
Total Non-Operating Income (Expense)
19.7325.223.947.33-0.78-0.33
Pretax Income
-460.56-412.95-258.77-210.95-156.81-107.79
Provision for Income Taxes
3.640.890.570.01-0.08-0.36
Net Income
-464.2-413.84-259.34-210.96-156.73-107.43
Net Income to Common
-464.2-413.84-259.34-210.96-156.73-107.43
Shares Outstanding (Basic)
17315213812311088
Shares Outstanding (Diluted)
17315213812311088
Shares Change (YoY)
18.45%9.76%12.21%12.21%24.98%103.14%
EPS (Basic)
-2.69-2.73-1.88-1.71-1.43-1.22
EPS (Diluted)
-2.69-2.73-1.88-1.71-1.43-1.22
Free Cash Flow
-423.09-376.63-214.59-188.39-106.37-83.54
Free Cash Flow Per Share
-2.44-2.48-1.55-1.53-0.97-0.95
EBITDA
-486.75-437.78-282.48-218.08-155.91-108.05
EBIT
-487.17-438.15-282.71-218.28-156.03-108.12
Effective Tax Rate
-0.79%-0.22%-0.22%-0.00%0.05%0.33%
Updated Feb 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q